Loading…
← CockpitCompetitor Analysis › 300015.SZ Aier Eye Hospital Group Co., Ltd. Class AOpen in the cockpit ↗

Aier Eye Hospital Group Co., Ltd. Class A300015.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical/Nursing Services

China's largest eye-hospital chain, providing cataract, refractive and other ophthalmic care through a national hospital network.

≈ A Chinese HCA Healthcare focused purely on eye careMomentum leader 91
Mkt cap
$12.5B
US dollars, full cap
Free float
52%
of shares outstanding
$/day
$125M
20-day average traded
Fwd P/E
30.1×
forward earnings
ROIC−WACC
+6.7 pp
WACC 11.2%
Hurdle
-2 pp
Req g minus delivered
Next earnings
156 days
23 Apr 2027
Close · CNYCN¥9.08
1D-0.8%
1W+4.6%
1M+14.4%
3M+3.6%
6M-14.2%
YTD-17.3%
1Y-24.6%
ATR %2.4%
52w lowhigh27.6% off high

What Aier Eye Hospital does

China's largest eye-hospital chain, providing cataract, refractive and other ophthalmic care through a national hospital network.

Is paid by patients and insurers for each procedure, with refractive surgery and optical services paid for by patients themselves and cataract surgery largely covered by public insurance. It grows by building flagship hospitals in provincial capitals and surrounding them with smaller city and county hospitals, often with local partners. Chen Bang is the founder and controlling shareholder.

In one line: A Chinese HCA Healthcare focused purely on eye care.

Products and services

  • Cataract surgery
  • Refractive (LASIK) surgery
  • Other ophthalmic services

Customers

  • Patients needing eye care across China and select

Where it sits in the supply chain

  • Health care
  • Hospital/clinical services
  • Ophthalmology hospitals and clinics

What could go right

  • Rising demand for elective eye surgery
  • Hospital network expansion

What could go wrong

  • High expansion capex/goodwill risk
  • Local competition and pricing pressure

Moat: narrow (scale, brand, distribution). Largest branded eye-hospital network in China with scale advantages in equipment and specialist recruiting.

Headquarters: Changsha, Hunan, China · Founded: 2003 · Employees: 42,817

Named competitors

  • He Eye Hospital Group private or unlisted

Aier Eye Hospital at a glance

Size Aier Eye Hospital (300015.SZ) is a China Health Care company (Medical/Nursing Services) with a market value of $12.5B, the 182nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥9.08 on 18 Nov 2026.

Performance Over six months the shares fell 14.2%, against +16.9% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 19 in its peer set.

Growth Revenue grew 4.7% over the last twelve months (peer median +11.8%); the operating margin is 20.5% (peer median 9.6%).

Valuation It trades at 30.1× forward earnings against a peer median of 20.1× (6th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -2 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 6.7 points above its cost of capital (11.2% WACC).

Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 118300015.SZ 89
Six months, rebased to 100: Aier Eye Hospital against the median of its 19 peers (local-currency closes).

Aier Eye Hospital financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥23.2BCN¥22.3BCN¥20.9BCN¥20.3BCN¥16.1B
Revenue growth—+7%+3%+26%—
Gross profitCN¥12.1BCN¥10.3BCN¥9.60BCN¥10.1BCN¥7.91B
EBITDAn/aCN¥6.91BCN¥6.40BCN¥6.94BCN¥5.28B
Net incomeCN¥2.42BCN¥3.24BCN¥3.56BCN¥3.36BCN¥2.52B
Free cash flowCN¥3.51BCN¥3.94BCN¥3.26BCN¥4.45BCN¥3.14B
Capital expenditureCN¥1.82BCN¥2.09BCN¥1.83BCN¥1.46BCN¥1.39B
Total debtCN¥7.80BCN¥7.59BCN¥7.49BCN¥6.65BCN¥5.90B

Quarterly statements and history in the cockpit →

Aier Eye Hospital competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%+75%-40%-20%0%+20%EHCBTSGFMEENSGSOLVDVASHLRDNTPHIACONLFSTLHOPCHBLLNHIMSMCOV-BLALPATHLABACHC300015.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Aier Eye Hospital is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%50×100×EHCBTSGFMEENSGSOLVDVASHLRDNTPHIACONLFSTBLLNMCOV-BLALPATHLAB300015.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Aier Eye Hospital is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%25%50%75%EHCBTSGFMEENSGDVASHLRDNTPHIALFSTLHOPCH3774BLLNMCOV-BLALPATHLAB300015.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Aier Eye Hospital is the large dot.

Aier Eye Hospital competitors and peer comparison

How Aier Eye Hospital compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Aier Eye Hospital against its 19 peers (data as of 18 Nov 2026)
Measure300015.SZPeer medianRank in peer set
1-month return+14.4%+6.6%5th highest of 20
6-month return-14.2%+16.9%3rd lowest of 19
Distance from 52-week high-27.6%-9.0%4th lowest of 20
Revenue growth (TTM)+4.7%+11.8%7th lowest of 20
Operating margin20.5%9.6%2nd highest of 20
Forward P/E30.1×20.1×6th most expensive of 18
Growth the price implies (Req g, 7 yrs)11.8%13.6%8th least demanding of 17
Growth delivered (Del g)+13.4%+12.5%8th highest of 17
Hurdle (Req g minus delivered)-1.6 pp+1.8 pp7th least demanding of 17
ROIC minus cost of capital+6.7 pp+0.5 pp4th highest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Aier Eye Hospital 300015.SZChina$12.5B-14%+5%21%30.1×11.8%+13.4%
Encompass Health EHCUnited States$13.2B+27%+9%18%20.1×5.7%+5.0%
BrightSpring Health Services BTSGUnited States$13.6B+17%+23%4%28.8×24.9%+18.3%
Fresenius Medical Care FME.DEGermany$11.2B+3%-1%11%9.5×-4.8%+1.9%
Ensign ENSGUnited States$10.7B+3%+17%9%21.3×12.7%+16.5%
Solventum SOLVUnited States$14.7B+14%-3%8%11.7×n/an/a
DaVita DVAUnited States$10.2B-18%+6%15%10.1×-2.5%+3.4%
Sonic Healthcare SHL.AXAustralia$6.87B+6%+14%9%17.4×9.1%+3.5%
RadNet RDNTUnited States$5.66B+32%+21%5%93.2×38.8%+13.7%
Koninklijke Philips PHIA.ASNetherlands$29.0B+17%-1%10%16.4×5.9%+0.6%
Concentra Group Holdings Parent CONUnited States$5.31B+65%+12%17%22.3×3.6%+7.9%
Lifestance Health LFSTUnited States$5.24B+79%+23%6%51.8×33.4%+30.4%
Labcorp LHUnited States$30.1B+44%+6%11%19.3×14.5%0.0%
Option Care Health OPCHUnited States$4.75B+43%+4%6%15.7×2.0%+13.2%
Fameglow 3774.HKHong Kong$4.54Bn/a+36%11%n/a57.4%+48.4%
BillionToOne BLLNUnited States$4.37B+7%+72%10%115.3×22.8%+71.9%
Hims & Hers Health HIMSUnited States$4.00B-26%+30%-1%n/an/an/a
Medicover MCOV-B.STSweden$3.87B+21%+3%7%36.1×19.6%+20.2%
Dr. Lal PathLabs LALPATHLAB.NSIndia$3.53B+15%+17%24%50.5×32.3%+11.8%
Acadia Healthcare ACHCUnited States$3.49B+56%+4%10%18.6×n/an/a

Questions

Who are Aier Eye Hospital's main competitors?
Named competitors: He Eye Hospital Group (private or unlisted). The cockpit's measured peer set (industry) also includes Encompass Health (EHC), BrightSpring Health Services (BTSG), Fresenius Medical Care (FME.DE), Ensign (ENSG), Solventum (SOLV), DaVita (DVA).
Is Aier Eye Hospital expensive compared with its peers?
On forward p/e it trades at 30.1× against a peer median of 20.1×, 6th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -2 pp: the price already allows for a slowdown.
How has Aier Eye Hospital stock performed?
Over six months to 18 Nov 2026 the shares returned -14.2% against +16.9% for the median peer; over one year -24.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.